particl
vlp
complex
capsid
protein
mimic
overal
structur
parent
viru
void
viral
genet
materi
noninfecti
particl
possess
biolog
desir
trait
attribut
particul
viral
structur
grgacic
anderson
pattenden
middelberg
niebert
lipin
particular
interest
effici
recognit
cellular
uptak
process
host
immun
system
vlp
technolog
rapidli
expand
field
aim
embrac
featur
achiev
specif
biolog
outcom
vlp
amen
broad
rang
modif
includ
encapsul
chemic
conjug
genet
manipul
mellado
castilho
carrondo
alv
versatil
vlp
combin
natur
abil
packag
deliv
nucleic
acid
prompt
use
biodegrad
deliveri
agent
gene
therapi
takamura
et
al
tegerstedt
franzen
et
al
success
packag
peptid
protein
synthet
drug
vlp
reveal
prospect
role
drug
deliveri
kaczmarczyk
sitaraman
young
hugh
chatterje
zdanowicz
chroboczek
diagnost
field
vlp
contain
gadolinium
shown
potenti
molecular
imag
contrast
agent
schwarz
dougla
applic
vlp
research
surrog
studi
clearanc
live
virus
also
demonstr
johnson
brorson
frey
dhar
cetlin
loisi
et
al
forefront
vlp
technolog
impact
howev
vaccinolog
licens
prophylact
vlp
vaccin
porcili
demonstr
vlp
vaccin
safe
effect
vlp
technolog
overcom
numer
drawback
associ
tradit
method
vaccin
product
specif
infecti
natur
associ
live
inactiv
vaccin
lengthi
product
time
synthet
biolog
redesign
construct
novel
artifici
biolog
organ
pathway
process
revolution
vaccin
product
appli
vlp
synthet
biolog
allow
precis
predict
control
composit
assembl
viral
capsid
turn
widen
rang
unrel
antigen
modul
incorpor
consequ
vaccin
engin
prophylact
therapeut
mean
jen
bachmann
match
specif
viral
strain
schwartzman
et
al
gener
multival
pushko
et
al
broadli
vaccin
moreov
new
bioprocess
modal
includ
vitro
assembl
chuan
fan
lua
middelberg
express
bundi
franciszkowicz
swartz
open
way
reimagin
vaccin
product
process
influenza
one
best
exampl
omic
precis
genom
revolution
vaccin
design
dedic
databas
detail
complet
accur
influenza
genom
inform
creat
readili
access
worldwid
mchardi
adam
last
decad
vast
wealth
data
translat
knowledg
conjunct
synthet
biolog
aid
design
vlp
vaccin
candid
prabakaran
et
al
pushko
et
al
pushko
et
al
novel
biolog
entiti
undoubtedli
safer
potenti
broadli
reactiv
previou
counterpart
ie
tradit
commerci
avail
live
attenu
influenza
vaccin
sever
genom
applic
aid
identif
novel
antigen
liao
et
al
name
revers
vaccinolog
compar
function
genom
revers
vaccinolog
combin
genom
proteom
bioinformat
identifi
virtual
potenti
protect
antigen
code
region
within
genom
bambini
rappuoli
rappuoli
compar
genom
primarili
use
design
broadli
protect
vaccin
allow
comparison
conserv
variabl
open
read
frame
within
speci
function
genom
allow
identif
protein
function
base
revers
genet
evalu
mutat
knockout
gene
express
analysi
transcriptom
bagnoli
et
al
bambini
rappuoli
rappuoli
sett
rappuoli
although
genom
per
se
contribut
significantli
design
mani
vaccin
candid
influenza
prabakaran
et
al
pushko
et
al
pushko
et
al
malaria
draper
et
al
wu
narum
fleuri
jen
yadava
human
immunodefici
viru
hiv
calazan
boggiano
lindsay
full
potenti
vaccin
develop
realiz
integr
proteom
immunom
bagnoli
et
al
moreov
coordin
deploy
omic
technolog
along
miniatur
bioprocess
screen
exampl
microbioreactor
microfluid
cell
cultur
system
aid
develop
assess
lead
acceler
manufactur
bhambur
kumar
rathor
gong
lei
hemmerich
noack
wiechert
oldig
immunom
specif
address
interfac
host
immun
system
pathogen
proteom
studi
subset
protein
epitop
recogn
host
immun
system
inform
use
valid
antigen
identifi
silico
andor
vitro
approach
evalu
whether
target
clinic
relev
immun
respons
ie
stimul
product
specif
cytokin
activ
specif
cell
type
et
al
exampl
immunom
applic
vlp
vaccin
design
glaxosmithklin
rt
vaccin
advanc
malaria
vaccin
candid
rt
chimer
vlp
larg
portion
plasmodium
circumsporozoit
protein
csp
display
protein
scaffold
hepat
b
surfac
antigen
wu
et
al
combin
system
biolog
genom
proteom
immunom
use
highlight
region
within
csp
immunogen
protect
human
thu
indispens
incorpor
chimer
vlp
mani
candid
identifi
one
prove
success
phase
iiab
efficaci
trial
draper
et
al
kazmin
et
al
structur
inform
use
reconfigur
engin
conserv
epitop
expos
area
exhibit
high
immunogen
insert
multipl
immunodomin
epitop
within
vlp
platform
liljeroo
malito
ferlenghi
bottomley
strategi
broaden
immun
respons
enhanc
exist
respons
weak
immunogen
antigen
identifi
conform
epitop
studi
interact
immun
system
provid
signific
inform
ration
antigen
design
anggraeni
et
al
mulder
et
al
encourag
recent
result
vlp
c
zhao
ao
yao
structur
biolog
emerg
power
tool
assist
ration
design
modern
hiv
vlp
vaccin
novel
protect
epitop
identifi
conform
epitop
map
studi
via
structur
biolog
liljeroo
et
al
malito
carfi
bottomley
addit
broad
potent
hiv
antibodi
discov
pool
memori
b
cell
use
structur
biolog
highlight
novel
site
vulner
hiv
envelop
glycoprotein
epitop
j
huang
et
al
incorpor
vlp
antigen
strateg
modifi
insert
extend
epitop
membran
proxim
extern
region
mper
zhai
zhong
zariffard
spear
qiao
provid
better
display
conserv
bind
site
captur
broadli
neutral
antibodi
ingal
et
al
structur
biolog
equal
inform
vlp
engin
capsid
protein
form
vlp
need
correctli
fold
ensur
function
induc
protect
humor
immun
respons
morpholog
characterist
vlp
assess
imag
technolog
cryoelectron
microscopi
atom
forc
microscopi
dynam
light
scatter
imag
method
provid
essenti
data
solv
structur
vlp
therefor
help
identifi
optim
vlp
insert
site
display
given
antigen
mani
vlp
platform
develop
far
use
design
approach
commonli
report
deriv
viral
structur
hepat
core
antigen
hbcag
murin
polyomaviru
mupyv
human
papillomaviru
hpv
bacteriophag
tabl
system
immunolog
emerg
area
research
use
broad
integr
multilevel
approach
studi
immun
system
identifi
immun
correl
protect
immunogen
signatur
davi
tato
furman
combin
recent
technolog
advanc
human
immunolog
system
immunolog
provid
guidanc
ration
vaccin
design
system
immunolog
allow
assess
cell
type
immun
system
includ
special
b
white
blood
cell
state
function
signal
molecul
encod
gene
bird
accumul
data
captur
snapshot
human
immun
system
provid
valuabl
inform
creation
human
immun
respons
model
may
later
translat
improv
vaccin
design
davi
et
al
system
immunolog
approach
previous
undertaken
investig
immun
respons
live
attenu
yellow
fever
vaccin
hou
et
al
muyanja
et
al
follow
immun
comprehens
character
immun
system
perform
provid
insight
vaccin
mechan
action
similar
method
later
appli
malaria
vaccin
rt
approach
led
identif
molecular
cellular
signatur
associ
protect
immunogen
uniqu
vaccin
kazmin
et
al
system
immunolog
may
also
play
import
role
design
vaccin
capabl
stimul
part
immun
system
address
current
vaccin
davi
et
al
vlp
ideal
test
candid
system
immunolog
approach
due
abil
stimul
immun
respons
well
prolif
respons
cytotox
lymphocyt
respons
gaus
et
al
correct
identif
epitop
stimul
immun
respons
crucial
design
novel
immunogen
epitop
region
within
antigen
recogn
receptor
patronov
doytchinova
potenti
epitop
map
use
bioinformat
comput
biolog
tool
howev
without
recent
improv
immunolog
character
method
identif
epitop
optim
stimul
human
immun
respons
becom
challeng
rappuoli
bottomley
doro
finco
de
gregorio
abil
isol
memori
b
cell
fac
follow
vitro
cultur
enabl
secret
suffici
amount
recombin
monoclon
antibodi
fragment
allow
antigen
screen
bind
function
assay
j
huang
et
al
ultim
goal
incorpor
specif
antigen
region
vlp
scaffold
thu
improv
vaccin
specif
gener
effect
vaccin
exampl
novel
vulner
site
hiv
envelop
glycoprotein
use
hiv
vlp
vaccin
design
j
huang
et
al
zhai
et
al
bioinformat
comput
biolog
tool
potenti
acceler
data
analysi
translat
result
applic
knowledg
foster
discoveri
new
lead
antigen
reduc
number
empir
experi
xiang
vaccin
design
inher
complex
labori
process
softwar
algorithm
databas
outlin
potenti
streamlin
vaccin
develop
via
identif
candid
antigen
may
otherwis
overlook
epitop
map
essenti
design
vaccin
capabl
mount
robust
respons
discoveri
epitop
reli
upon
immunolog
predict
softwar
netmhc
syfpeithi
epijen
epivax
describ
studi
epitop
predict
mani
softwar
avail
reach
posit
predict
valu
et
al
addit
interfac
platform
mhcbench
salomon
flower
allow
direct
evalu
variou
major
histocompat
complex
mhc
peptid
predict
algorithm
interfac
platform
prove
valuabl
user
unsur
predict
model
best
suit
need
epitop
predict
avail
softwar
support
algorithm
reach
discontinu
antigen
eg
cobepro
sweredoski
baldi
bcpred
fbcpred
dobb
honavar
continu
antigen
eg
epmeta
liang
et
al
posit
predict
valu
bioinformat
comput
biolog
also
assist
discoveri
conserv
epitop
sequenc
variabl
analysi
particularli
relev
deal
pathogen
capabl
evad
immun
system
due
high
mutat
rate
protein
variabl
server
pv
valuabl
tool
identif
conserv
epitop
facilit
develop
broadli
protect
vaccin
reinherz
rech
studi
pv
use
identifi
conserv
fragment
ectodomain
sever
databas
retain
classifi
data
experiment
verifi
vaccin
andor
vaccin
compon
thu
use
tool
vaccin
design
immun
epitop
databas
analysi
resourc
peter
et
al
http
wwwiedborg
collect
publish
experiment
data
character
immun
epitop
context
molecular
structur
recogn
epitop
immun
receptor
iedb
epitop
multipl
tool
identifi
epitop
vita
et
al
syfpeithi
databas
schuler
nastk
stevanovikc
http
wwwsyfpeithid
inform
mhc
class
ii
anchor
motif
bind
specif
conform
epitop
databas
offer
inform
protein
conform
antigendb
http
wwwimtechresinraghavaantigendb
store
sequenc
structur
origin
epitop
pathogen
antigen
ansari
flower
raghava
comput
optim
broadli
reactiv
antigen
cobra
methodolog
recent
develop
overcom
challeng
associ
antigen
divers
influenza
subtyp
carter
et
al
silico
approach
use
consensu
build
gener
number
antigen
candid
term
cobra
antigen
use
identifi
ha
antigen
broadli
protect
strain
display
antigen
vlp
demonstr
immunogen
efficaci
murin
model
valid
technolog
advent
novel
technolog
screen
discoveri
immunogen
antigen
target
advanc
synthet
biolog
one
engin
vlp
function
design
vaccin
increas
broader
immunogen
andor
improv
stabil
free
figur
collin
snaith
cottingham
gilbert
hill
lua
et
al
vlp
engin
enhanc
tune
immun
respons
vaccin
use
synthet
biolog
tool
one
harbor
immunogen
insid
outsid
vlp
upon
vaccin
capabl
trigger
earli
innat
immun
respons
enhanc
vaccin
effect
increas
vaccin
uptak
rosenth
chen
baker
putnam
delisa
immunomodulatori
agent
eg
pattern
recognit
receptor
ligand
dendrit
cell
target
antibodi
endoplasm
reticulum
target
peptid
boost
immun
respons
mainli
expans
specif
cell
product
cytokin
without
effect
vlp
divid
two
main
group
envelop
nonenvelop
envelop
vlp
capsid
acquir
lipid
layer
bud
host
cell
layer
absent
nonenvelop
vlp
mateu
insert
heterolog
antigen
otherwis
known
modular
nonenvelop
vlp
mainli
achiev
genet
fusion
chemic
conjug
peacey
wilson
baird
ward
size
insert
implic
vlp
assembl
correct
present
antigen
small
peptid
epitop
easili
insert
vlp
structur
without
affect
vlp
assembl
often
occur
modular
whole
larg
protein
domain
genet
fusion
popular
method
despit
mateu
chemic
conjug
support
insert
larg
antigen
preform
vlp
modif
perform
natur
occur
conjug
site
use
chemic
crosslink
enzym
patel
swartz
tang
xuan
ye
huang
qian
downsid
chemic
conjug
incur
cost
requir
product
vlp
epitop
well
conduct
chemic
conjug
chackerian
smith
haw
bundi
recent
develop
technolog
start
address
cost
technolog
challeng
exampl
plug
display
system
technolog
base
two
protein
tag
catcher
react
irrevers
close
proxim
catcher
fuse
vlp
tag
fuse
vaccin
target
form
vlp
vaccin
readi
use
brune
et
al
exampl
nonenvelop
vlp
use
display
foreign
antigen
hbcag
chu
et
al
hpv
protein
slupetzki
et
al
orourk
peabodi
chackerian
envelop
vlp
present
heterolog
membran
protein
ie
glycoprotein
nativ
configur
top
capsid
protein
without
need
engin
epitop
capsid
structur
process
call
pseudotyp
chua
et
al
kirchmeier
et
al
pseudotyp
one
alter
vlp
stabil
even
tropism
cronin
zhang
reiser
k
palomar
et
al
addit
transmembran
domain
within
foreign
viral
envelop
protein
replac
transmembran
domain
specif
virus
eg
vesicular
stomat
viru
improv
pseudotyp
effici
immunogen
kirchmeier
et
al
envelop
vlp
shown
promis
vaccin
candid
diseas
influenza
malaria
dengu
viru
chua
et
al
pitoiset
vazquez
bellier
engin
vlp
long
complex
process
often
unsuccess
insert
small
peptid
disrupt
vlp
structur
field
evolv
vlp
chimera
use
fundament
appli
research
mateu
murata
et
al
success
exampl
insert
larg
peptid
vlp
deriv
flock
hous
viru
engin
carri
receptor
domain
could
use
anthrax
antitoxin
well
vaccin
manayani
et
al
circul
virus
exhibit
high
antigen
variabl
high
mutat
rate
influenza
pose
substanti
challeng
current
vaccin
strategi
wibowo
et
al
novel
strategi
therefor
develop
creat
broadli
vaccin
highli
conserv
antigen
identifi
diverg
influenza
virus
broadli
reactiv
antigen
locat
within
membran
proxim
stalk
domain
hemagglutinin
protein
insert
vlp
demonstr
success
vaccin
candid
krammer
wiersma
rimmelzwaan
de
vri
broad
protect
also
possibl
simultan
display
multipl
antigen
distinct
prabakaran
et
al
pushko
et
al
schwartzman
et
al
chimer
carter
et
al
ha
antigen
differ
influenza
subtyp
within
vlp
sever
viral
structur
protein
bacteriophag
current
develop
vaccin
platform
target
varieti
pathogen
tabl
synthet
biolog
approach
widen
scope
potenti
antigen
modular
show
platform
modifi
overcom
specif
challeng
associ
vlp
vaccin
manufactur
figur
nonenvelop
vlp
structur
less
complex
envelop
counterpart
produc
prokaryot
lower
order
eukaryot
system
make
easili
scalabl
rapid
manufactur
presenc
lipid
bilay
envelop
vlp
necessit
use
eukaryot
host
express
increas
overal
product
time
cost
nonetheless
unlik
nonenvelop
vlp
envelop
vlp
permit
present
antigen
modul
requir
high
immunogen
desir
vaccin
attribut
potenti
translat
protect
target
infect
enhanc
immunogen
modular
antigen
must
strateg
insert
maxim
present
immun
system
modular
peptid
viral
protein
previous
report
de
filett
et
al
hayn
et
al
howev
low
surfac
express
inabl
peptid
adopt
nativ
conform
result
weak
immunogen
insert
site
et
al
platform
base
upon
hbcag
papillomaviru
bovin
human
flock
hous
viru
fhv
other
thu
engin
take
advantag
loop
demonstr
enhanc
immunogen
murata
et
al
slupetzki
et
al
ye
et
al
peptid
insert
expos
loop
protrud
surfac
vlp
make
access
immun
system
short
peptid
display
rel
simpl
structur
pose
littl
problem
modular
within
expos
loop
yet
complex
structur
requir
platform
engin
anggraeni
et
al
incorpor
epitop
scaffold
expos
loop
vlp
maintain
structur
properti
complex
peptid
shown
present
influenza
chain
fhv
platform
schneemann
et
al
strategi
howev
requir
detail
structur
knowledg
chosen
peptid
identif
suitabl
scaffold
fragment
antigen
insert
immunodomin
loop
hbcag
platform
requir
close
juxtapos
maintain
vlp
integr
walker
et
al
impos
consider
limit
upon
antigen
choic
support
modular
antigen
possess
extend
structur
splitcor
system
thu
devis
walker
et
al
divid
hbcag
core
protein
within
immunodomin
loop
yield
two
fragment
abl
form
vlp
coexpress
fusion
antigen
termini
either
fragment
coexpress
enabl
modular
antigen
may
otherwis
structur
incompat
display
whole
protein
domain
surfac
vlp
allow
present
multipl
antigen
epitop
increas
likelihood
epitop
adopt
nativ
conform
larg
size
howev
caus
steric
hindranc
result
compromis
vlp
assembl
lua
fan
chang
connor
middelberg
sever
strategi
develop
specif
modular
larg
antigen
long
flexibl
linker
engin
flank
antigen
loop
hbcag
platform
allow
spatial
separ
enabl
protein
insert
kratz
bottcher
nassal
though
effect
optim
linker
length
differ
antigen
need
empir
determin
steric
hindranc
also
address
case
reduc
antigen
content
surfac
vlp
exampl
peyret
et
al
engin
singl
polypeptid
compos
unmodifi
hbcag
fuse
chimer
hbcag
dual
express
construct
also
devis
coexpress
unmodifi
murin
polyomaviru
mupyv
display
kda
rotaviru
antigen
lua
et
al
tekew
fan
tan
middelberg
lua
although
method
lead
success
vlp
assembl
possibl
increas
antigen
mass
wherea
reduc
antigen
number
may
reflect
lower
immunogen
seen
synthet
deriv
rt
malaria
vaccin
pitoiset
et
al
nevertheless
inevit
mass
antigen
increas
rel
carrier
necessit
understand
optim
domain
display
larg
antigen
report
use
novel
platform
base
upon
hpv
protein
acinetobact
phage
thrane
et
al
thrane
et
al
brune
et
al
avitag
spytagspycatch
platform
allow
conjug
antigen
post
vlp
assembl
reaction
avitag
spontan
format
irrevers
isopeptid
bond
spytagspycatch
linker
alreadi
predefin
platform
remain
constant
permit
high
throughput
screen
vaccin
candid
addit
independ
product
antigen
differ
express
system
possibl
particular
interest
posttransl
modif
critic
immunogen
provid
steric
inhibit
attach
encapsul
protein
nucleic
acid
vlp
assembl
alter
immunogen
contribut
significantli
variat
vaccin
prepar
specif
limit
regard
host
contamin
clearli
stipul
licens
regul
host
contamin
remov
vlp
disassembl
ex
vivo
reassembl
necessit
licens
hpv
vlp
mccarthi
white
koenig
suzich
unfavor
complic
downstream
process
add
manufactur
cost
synthet
modif
hpv
mupyv
protein
led
develop
capsomer
platform
middelberg
et
al
schadlich
et
al
remov
carboxyl
termini
protein
yield
capsomer
incap
form
vlp
vivo
mupyv
capsomer
display
increas
stabil
although
less
immunogen
vlp
administ
adjuv
effect
middelberg
et
al
furthermor
quantit
process
studi
report
produc
e
coli
mupyv
capsomer
platform
capabl
produc
million
vaccin
dose
day
low
cost
highlight
suitabl
rapid
respons
vaccin
platform
chuan
wibowo
lua
middelberg
safe
robust
influenza
platform
illustr
aforement
broadli
immunoprotect
capabl
vlp
platform
multipl
subtyp
ha
antigen
display
either
individu
schwartzman
et
al
simultan
pushko
et
al
sequeira
et
al
tretyakova
pearc
flores
tumpey
pushko
base
vaccin
afford
protect
viru
challeng
multipl
speci
liu
massar
et
al
pyo
et
al
subject
recent
influenza
phase
ii
clinic
trial
vast
major
studi
produc
util
either
mammalian
cell
line
transient
stabl
express
insect
cell
line
mainli
transient
express
use
baculoviru
express
system
synthet
biolog
recent
appli
platform
overcom
drawback
produc
vlp
baculoviru
easili
separ
owe
current
limit
purif
analyt
techniqu
recent
develop
biorthogon
label
strategi
enabl
distinct
baculoviru
ha
contain
thu
allow
greater
control
vaccin
contamin
carvalho
et
al
system
involv
fluoresc
label
noncanon
amino
acid
incorpor
ha
protein
within
envelop
vlp
combinatori
analysi
use
size
exclus
chromatographi
sec
confoc
microscopi
flow
cytometri
demonstr
possibl
obtain
vlp
independ
baculoviru
present
synthet
modif
hold
promis
analyt
tool
laboratori
level
howev
given
use
fluoresc
reagent
cost
develop
requir
address
practic
industri
scale
choic
express
host
cultur
paramet
greatli
influenc
express
yield
kushnir
streatfield
yusibov
lua
et
al
et
al
vicent
peixoto
carrondo
alv
e
coli
far
superior
express
system
term
cost
yield
speed
make
popular
choic
product
singl
capsid
protein
nonenvelop
vlp
x
huang
wang
zhang
xia
zhao
inabl
e
coli
perform
posttransl
modif
mean
complex
minim
case
posttransl
complex
modif
requir
use
manufactur
licens
vlp
vaccin
porcili
yet
vaccin
cost
high
owe
partli
low
product
yield
synthet
engin
baculoviru
vector
use
combin
transcript
translat
element
increas
yield
system
escribano
liu
zhang
et
al
similarli
synthet
design
express
cassett
contain
rearrang
genet
regulatori
element
transcript
factor
transcript
enhanc
sequenc
link
differenti
promot
increas
express
cell
viabil
porcin
circoviru
vlp
rabbit
hemorrhag
diseas
vlp
et
al
maintain
vlp
integr
anoth
key
consider
multiprotein
capsid
specif
protein
ratio
requir
prevent
aggreg
unassembl
vlp
l
palomar
ramirez
et
al
protein
stoichiometri
control
mammalian
express
system
manipul
multipl
infect
transfect
ratio
thermodynam
arevalo
wong
ross
l
palomar
ramirez
et
al
though
involv
increas
process
cost
differ
strength
promot
also
synthet
integr
multicistron
vector
result
differenti
express
individu
protein
jere
oneil
potgiet
van
dijk
howev
given
optim
ratio
vari
depend
specif
vlp
individu
optim
requir
surpass
drawback
tradit
coinfect
strategi
andor
larger
unstabl
viral
vector
modular
express
system
number
gene
express
ration
distribut
recombin
viral
construct
stabl
cell
line
adopt
strategi
proven
alreadi
success
product
multival
influenza
vlp
use
insect
high
five
platform
sequeira
et
al
vaccin
product
scale
cost
puriti
vari
depend
vlp
purif
process
centrifug
depth
tangenti
flow
filtrat
use
initi
clarif
concentr
step
easili
scale
industri
level
chromatograph
method
use
remov
host
cell
dna
impur
densiti
gradient
ultracentrifug
easili
scalabl
anion
exchang
sec
costli
highlight
need
effici
method
nonchromatograph
strategi
base
upon
aqueou
system
atp
process
present
use
enzym
product
industri
level
develop
vlp
purif
high
yield
rotaviru
vlp
purifi
insect
cell
supernat
use
atp
although
puriti
rel
poor
benavid
et
al
recent
singl
multistep
atp
use
purifi
human
particl
insect
cell
lysat
effio
et
al
puriti
level
greater
yet
appear
expens
yield
monolith
technolog
present
rapid
scalabl
method
offer
distinct
advantag
classic
chromatographi
vicent
et
al
hbsag
vlp
yeast
homogen
effect
purifi
use
hydroxyl
derivat
monolith
burden
jin
podgornik
bracewel
compar
densiti
gradient
centrifug
monolith
yield
gag
vlp
chines
hamster
ovari
cho
cell
supernat
steppert
et
al
sulfat
cellulos
membran
absorb
offer
signific
improv
convent
ion
exchang
membran
absorb
carvalho
fortuna
et
al
easili
scale
reduc
number
requir
process
step
may
qualifi
gener
purif
platform
vaccin
technolog
hold
promis
vlp
purif
warrant
investig
vlp
character
critic
step
analyz
vlp
stabil
integr
addit
inform
obtain
regard
impur
signific
impact
vaccin
efficaci
biosafeti
robust
analyt
tool
use
tandem
provid
comprehens
character
data
tradit
method
western
blot
analysi
sec
ultracentrifug
other
transmiss
electron
microscopi
demand
high
invest
cost
extens
prepar
work
specif
expert
method
allow
swift
analysi
current
develop
tekew
et
al
develop
high
throughput
method
base
upon
dynam
light
scatter
technolog
permit
rapid
analysi
capsomer
stabil
base
hydrodynam
radiu
size
exclus
ultrahigh
perform
liquid
chromatographi
method
also
develop
vlp
sampl
analyz
min
use
interlac
inject
techniqu
allow
accur
quantit
vlp
aggreg
effio
oelmeier
hubbuch
recent
univers
analyt
tool
influenza
vlp
quantif
base
biolay
interferometri
technolog
appli
octet
platform
develop
carvalho
moleirinho
et
al
overal
analyt
method
support
rapid
character
larg
sampl
set
aid
effici
vaccin
develop
increas
cost
regulatori
uncertainti
associ
produc
new
vaccin
long
challeng
vaccin
manufactur
ulmer
valley
rappuoli
intricaci
vaccin
manufactur
demand
substanti
amount
expert
contribut
significantli
cost
plotkin
et
al
expens
associ
vaccin
r
test
manufactur
well
poor
profit
margin
compar
current
drug
market
led
dramat
fall
fund
pharmaceut
compani
offit
howev
declin
thought
prematur
demonstr
throughout
review
vlp
technolog
advanc
rapidli
strong
focu
develop
platform
capabl
improv
vlp
product
yield
enabl
rapid
product
safer
cheaper
vaccin
particularli
combin
bioprocess
system
progress
set
continu
financi
invest
provid
sourc
nation
govern
intern
organ
philanthrop
bodi
particular
gavi
vaccin
allianc
balaji
bill
melinda
gate
foundat
http
wwwgatesfoundationorg
motiv
deliv
afford
vaccin
third
world
countri
world
biggest
vaccin
market
ensur
vaccin
puriti
safeti
efficaci
stabil
regulatori
author
govern
everi
stage
vaccin
manufactur
raw
materi
product
process
clinic
trial
beyond
includ
assess
certif
safe
viabl
manufactur
process
plotkin
et
al
meet
regulatori
requir
complic
process
particularli
manufactur
vaccin
oversea
market
util
newli
develop
bioprocess
streamlin
upstream
downstream
process
util
gener
vlp
base
vlp
platform
technolog
expect
reduc
regulatori
load
individu
vaccin
given
regul
base
purif
becom
well
character
vlp
platform
may
even
fast
track
vaccin
deliveri
respons
pandem
circumst
vaccinolog
experienc
impress
technolog
revolut
enabl
move
vaccin
develop
beyond
rule
pasteur
empir
approach
use
disciplin
system
biolog
immunolog
comput
biolog
assist
ration
vaccin
design
modern
approach
inde
last
decad
wit
trend
toward
use
altern
vaccin
design
attenu
pathogen
vlp
emerg
power
versatil
platform
product
today
vlp
use
vaccin
unmodifi
viral
assembl
parent
virus
also
scaffold
display
heterolog
antigen
addit
tremend
invest
made
develop
new
technolog
capabl
deciph
pathogen
biolog
vaccin
mechanist
respons
b
store
curat
extract
data
biolog
refer
databas
machin
learn
algorithm
use
inform
epitop
predict
modular
design
complement
synthet
biolog
inform
provid
basi
engin
vlp
function
develop
gener
vlp
platform
offer
potenti
streamlin
bioprocess
parallel
infrastructur
predict
biosafeti
also
abil
manufactur
vaccin
unrel
virus
pathogen
sourc
ie
bacteria
parasit
protozoan
although
unabl
deliv
market
product
date
technolog
massiv
potenti
provid
near
futur
solut
untarget
infecti
agent
eg
bacteria
hiv
malaria
tuberculosi
importantli
reduc
vaccin
develop
time
manufactur
cost
associ
current
vaccin
platform
univers
queensland
uq
file
patent
use
mupyv
vaccin
platform
l
h
l
l
p
j
contribut
patent
employ
uq
hold
indirect
interest
intellectu
properti
